Cancer clinical trials in the region Auvergne-Rhône-Alpes

495 currently recruiting clinical trials
Region Auvergne-Rhône-Alpes

Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06154291 #2023-505266-29-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Xenothera SAS
Phase 1 / Phase 2 Breast cancer Lung cancer Colon cancer Rectal cancer Pancreas cancer Stomach and esophageal cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06154291 #2023-505266-29-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction Esophagus Epithelial ovarian cancer
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC Adenocarcinoma
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Xenothera SAS
Phase 1 / Phase 2 Acute leukemia #NCT05580861 #2024-513084-38-00
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
FLT3-ITD
4 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 1 / Phase 2 Acute leukemia #NCT04065399 #2020-004104-34
Required histologic types
Acute lymphoblastic leukemia (ALL) Other acute leukemia
Required central nervous system lesions
None Treated / Controled
Required genetic anomalies
KMT2A
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2 Acute leukemia #NCT04065399 #2020-004104-34
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None Treated / Controled
Required genetic anomalies
KMT2A
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2 Acute leukemia #NCT04065399 #2020-004104-34
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None Treated / Controled
Required genetic anomalies
NPM1
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2 Acute leukemia #NCT04065399 #2020-004104-34
Required central nervous system lesions
None Treated / Controled
Required genetic anomalies
Other mutation KMT2A NPM1
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2 Acute leukemia #NCT04150497
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required histologic sub types
B-cell (B-ALL)
Required number of previous lines of therapy
2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Cellectis SA
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05410145 #2023-508517-16-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
D3 Bio (Wuxi) Co., Ltd
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06888921 #2025-521125-33-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy
8 recruiting sites
Compugen Ltd